Sumatriptan-Vertex, 50 mg 2 pcs

Sumatriptan is an antimigraine agent. It is a specific and selective agonist of 5-NT1-serotonin receptors localized mainly in the blood vessels of the brain, and does not act on other subtypes of 5-NT-serotonin receptors (5-NT 2-7). < br>

Causes narrowing of the carotid arterial bed vessels, which supply blood to the extracranial and intracranial tissues (dilation of the cerebral membrane vessels and/or their edema is the main mechanism of migraine development in humans), while not having a significant effect on cerebral blood flow. < br>

Suppresses the activity of receptors of trigeminal nerve afferent fiber endings in the dura mater (as a result the release of sensory neuropeptides is reduced). It eliminates nausea and photophobia associated with migraine attack.

< br> In 50-70% of cases it quickly eliminates the attack when taken orally in a dose of 25-100 mg. Within 24 h, a relapse may occur in 1/3 of cases requiring reapplication. Onset of action is 30 min. After oral administration at a dose of 100 mg.

< br>.

Indications

Relief of migraine attacks and Horton’s syndrome (histamine cephalgia).

Pharmacological effect

Pharmacological action

Migraine treatment; serotonin 5-HT1 receptor agonist. The therapeutic effect of sumatriptan is apparently due to two mechanisms: the substance excites serotonin 5-HT1 receptors in the smooth muscles of the vessels of the carotid artery system and causes their narrowing. The carotid arteries supply blood to the tissues of the head, incl. meninges; The occurrence of migraine attacks is associated with the expansion of blood vessels in the meninges. In addition, sumatriptan activates the receptors of the endings of the afferent fibers of the trigeminal nerve in the dura mater, as a result of which the release of sensory neuropeptides decreases. Sumatriptan does not penetrate the blood-brain barrier well and, according to experimental data, does not have actual analgesic properties.

The effect of sumatriptan usually occurs 30 minutes after oral administration and 10-15 minutes after subcutaneous administration.

Special instructions

Use for liver dysfunction

Use with caution in case of liver dysfunction.

Use for renal dysfunction

Use with caution in case of impaired renal function.

Use in children

Safety and effectiveness of use in children and adolescents under 18 years of age have not been established.

Sumatriptan is not used to prevent migraine attacks.

Use with caution in patients with impaired liver and kidney function, as well as in patients with epilepsy or other disorders of brain function.

When stopping attacks, it is advisable to start treatment as early as possible, however, the administration of sumatriptan during the aura period, before the appearance of other symptoms, may not prevent the occurrence of headache.

When treated with sumatriptan, symptoms sometimes occur that resemble angina attacks – pain, a feeling of constriction in the chest. In this regard, sumatriptan should not be used if undiagnosed heart and vascular diseases are suspected, until appropriate examination has been carried out.

If there is no effect on the first dose of sumatriptan, it is necessary to verify the diagnosis.

Safety and effectiveness of use in children and adolescents under 18 years of age have not been established.

Impact on the ability to drive vehicles and machinery

With migraine, as well as during therapy with sumatriptan, drowsiness may develop. Therefore, during the period of use, patients should be especially careful when driving and engaging in other potentially hazardous activities that require a high speed of psychomotor reactions.

Active ingredient

Sumatriptan

Composition

Active ingredient: sumatriptan

Pregnancy

Clinical experience with the use of sumatriptan during pregnancy is limited, and therefore its use is contraindicated.

Should be used with caution during lactation. It is not recommended to breastfeed your baby for 24 hours after taking sumatriptan.

Contraindications

IHD, arterial hypertension; simultaneous use of drugs containing ergot alkaloids or compounds close to them, lithium preparations, neuronal serotonin reuptake inhibitors; simultaneous use of MAO inhibitors and a period of up to 14 days after their discontinuation; hypersensitivity to sumatriptan.

Side Effects

From the central nervous system: dizziness, weakness, drowsiness.

From the cardiovascular system: arterial hypotension or short-term increase in blood pressure, bradycardia or tachycardia.

From the digestive system: nausea, vomiting.

Dermatological reactions: skin rash, erythema, itching.

Local reactions: with subcutaneous injection – short-term pain at the injection site.

Other: sensation of warmth, tingling, pain, pressure or constriction in different parts of the body.

Interaction

When used simultaneously with lithium salts, cases of the development of serotonin syndrome have been described.

When used simultaneously with moclobemide, the bioavailability of moclobemide increases in the absence of clinical manifestations.

When used concomitantly with rizatriptan, there is a risk of additive hyperstimulation of serotonin 5-HT1 receptors; with ergotamine – vasospasm may develop.

With the simultaneous use of St. John’s wort herb preparations, it is possible to enhance the serotonergic effects and develop side effects.

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25°C.

Shelf life

2 years

Manufacturer

Vertex, Russia